<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032106</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-19028</org_study_id>
    <secondary_id>NCI-2019-01223</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>R37CA226682</secondary_id>
    <nct_id>NCT04032106</nct_id>
  </id_info>
  <brief_title>HPV Vaccine Intervention for Young Sexual Minority Men</brief_title>
  <official_title>A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV
      vaccine initiation and completion among young individuals who report having a history of
      same-sex partners, being sexually attracted to males, or identify as gay, bisexual, or queer
      (i.e., sexual minority males). The Outsmart HPV intervention, which is a population-targeted,
      individually-tailored mHealth intervention that includes vaccine reminders, may increase HPV
      vaccine initiation and completion among unvaccinated young sexual minority individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the efficacy of the Outsmart HPV intervention on increasing HPV vaccine
      initiation and completion.

      II. Identify mediators that explain the relationship between study arm and HPV vaccine
      initiation and completion.

      III. Determine if intervention efficacy differs across key demographic and health-related
      characteristics of participants.

      OUTLINE: Participants are randomized to 1 of 3 groups.

      GROUP A: Participants receive standard information about HPV and HPV vaccine via a
      mobile-friendly website.

      GROUP B: Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e.
      reminders that do not give participants the option to respond).

      GROUP C: Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders
      that allow participants to respond).

      Participants in all study group are followed for 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants are not aware of the research questions being tested in the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Human papillomavirus (HPV) vaccine initiation and completion</measure>
    <time_frame>Baseline up to 9 months</time_frame>
    <description>Number and proportion of participants who initiate and complete the HPV vaccine series during the study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in theoretical constructs</measure>
    <time_frame>Baseline up to 9 months</time_frame>
    <description>Changes in theoretical constructs from baseline to follow-up timepoints as assessed by study surveys</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential moderators</measure>
    <time_frame>Baseline up to 9 months</time_frame>
    <description>Demographic and health-related characteristics as assessed by study surveys</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1995</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Group A (standard HPV information)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Outsmart HPV, unidirectional vaccine reminders)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Outsmart HPV, interactive vaccine reminders)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard information about HPV and HPV vaccine</description>
    <arm_group_label>Group A (standard HPV information)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Receive Outsmart HPV intervention</description>
    <arm_group_label>Group B (Outsmart HPV, unidirectional vaccine reminders)</arm_group_label>
    <arm_group_label>Group C (Outsmart HPV, interactive vaccine reminders)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group A (standard HPV information)</arm_group_label>
    <arm_group_label>Group B (Outsmart HPV, unidirectional vaccine reminders)</arm_group_label>
    <arm_group_label>Group C (Outsmart HPV, interactive vaccine reminders)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Text Message-Based Intervention</intervention_name>
    <description>Receive unidirectional text message vaccine reminders</description>
    <arm_group_label>Group B (Outsmart HPV, unidirectional vaccine reminders)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Text Message-Based Intervention</intervention_name>
    <description>Receive interactive text message vaccine reminders</description>
    <arm_group_label>Group C (Outsmart HPV, interactive vaccine reminders)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cisgender male

          -  Ages 18-25

          -  Sexual minority (reports ever having oral or anal sex with a male or being sexually
             attracted to males; or identifies as gay, bisexual, or queer)

          -  Lives in the United States (US)

          -  Has not received any doses of HPV vaccine

          -  Did not participate in the pilot study

          -  Read English

          -  Able to provide informed consent (inferred by completing the screener survey and
             consent form)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cisgender male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Reiter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>1-800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie-Laurie McRee, PhD</last_name>
      <phone>612-626-0162</phone>
      <email>almcree@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Reiter</last_name>
      <phone>614-292-4803</phone>
      <email>reiter.36@osu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Reiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Paul Reiter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Men</keyword>
  <keyword>Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

